Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Rosmarin

Dermatology Indianapolis, IN Medical Doctor

NPI 1730353665 CMS profile 1010770

550 University Blvd Ste 3240, Indianapolis, IN 46202

Open in the dashboard

General payments

$1,123,361

950 records reported · program years 2019–2025

Research payments

$23,667

Paid to them · 29 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,311,447 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Rosmarin of Indianapolis, IN is reported in the CMS Open Payments database as having received $1,123,361 across 950 general payments and $23,667 in research payments paid to them. Separately, studies naming them as principal investigator received $3,311,447 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $80,711 50
2025 Research $12,690 11
2024 General $92,228 77
2024 Research $1,402 9
2023 General $90,074 74
2023 Research $125 1
2022 General $267,876 215
2022 Research $299 1
2021 General $199,481 130
2021 Research $1,641 1
2020 General $147,849 89
2020 Research $4,363 3
2019 General $245,142 315
2019 Research $3,146 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Rosmarin
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to David Rosmarin were reported at $80,711. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year David Rosmarin Dermatology median Middle half National median
2019 $245,142 $454 $129–$1,240 $163
2020 $147,849 $235 $81–$756 $114
2021 $199,481 $377 $108–$1,108 $132
2022 $267,876 $514 $143–$1,391 $149
2023 $90,074 $607 $159–$1,674 $160
2024 $92,228 $751 $204–$1,903 $164
2025 $80,711 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Incyte Corporation $152,657 112 payments
  2. Genzyme Corporation $120,347 73 payments
  3. Lilly USA, LLC $116,055 152 payments
  4. Eli Lilly and Company $115,879 119 payments
  5. Novartis Pharmaceuticals Corporation $111,639 80 payments
  6. AbbVie, Inc. $102,165 104 payments
  7. Pfizer Inc. $74,374 39 payments
  8. Regeneron Healthcare Solutions, Inc. $65,395 67 payments
  9. Amgen Inc. $63,866 57 payments
  10. Janssen Scientific Affairs, LLC $48,668 36 payments
  11. Other $152,317 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $565,484 235 payments
  2. Consulting Fee $420,372 125 payments
  3. Travel and Lodging $78,457 260 payments
  4. Honoraria $42,810 15 payments
  5. Food and Beverage $16,173 311 payments
  6. Education $65 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $144,866 90 payments
  2. OPZELURA $98,862 75 payments
  3. TALTZ $94,849 101 payments
  4. TREMFYA $67,312 55 payments
  5. DUPIXENT Inflammation And Immunology $64,339 66 payments
  6. Otezla $61,616 56 payments
  7. COSENTYX Immunology $56,677 25 payments
  8. SKYRIZI $43,179 39 payments
  9. COSENTYX Dermatology $39,076 42 payments
  10. EUCRISA $37,926 19 payments
  11. Other $167,354 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $13,630 12 payments
  2. Amgen Inc. $2,893 1 payment
  3. Regeneron Pharmaceuticals, Inc. $2,096 2 payments
  4. Eli Lilly and Company $2,004 4 payments
  5. Novartis Pharmaceuticals Corporation $1,641 1 payment
  6. AbbVie, Inc. $1,402 9 payments

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$782

Medicare's payments for the services billed

Medicare patients

13

Average age 74

Services billed

27

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TAPINAROF
  • Dermavant Sciences, Inc. $27,535
$27,535 — —
OPZELURA
  • Incyte Corporation $20,432
$20,432 — —
DUPIXENT
  • GENZYME CORPORATION $14,025
$14,025 — —
LITFULO
  • PFIZER INC. $10,867
$10,867 — —
TALTZ
  • Eli Lilly and Company $2,000
  • Lilly USA, LLC $23
$2,023 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

979 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record